← ANALYST RATINGS · TIPRANKS
FocalTherics (FOCL): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy1 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $7.00, the highest $10.00, the lowest $4.00. The average is +71.1% from the last price of $4.09.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $10.00 | Buy | +144.5% | Reiterated | 01.10.26on TipRanks 10:09 | −3.5%next day −3.5% · 5 days −5.8% | ↗ |
| Jason Bednar★★★★★★★★★★#11450 · hits 46% · avg −2.5% | Piper Sandler | $4.00 | Hold | −2.2% | Reiterated | 29.09.26on TipRanks 06:50 | +0.4%next day −1.3% · 5 days −7.9% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $4.50 | Hold | +10.0% | Reiterated | 28.08.26on TipRanks 11:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $4.00 | Hold | −2.2% | Reiterated | 28.08.26on TipRanks 11:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $4.00 → $4.50+12.5% | Hold | +10.0% | Reiterated | 28.08.26on TipRanks 11:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $4.00 | Sell | −2.2% | Downgrade | 28.08.26on TipRanks 11:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $4.50 | Hold | +10.0% | Reiterated | 28.08.26on TipRanks 11:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $4.50+12.5% | Hold | +10.0% | Reiterated | 28.08.26on TipRanks 11:05 | — | |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $15.00 | Buy | +266.7% | Initiated | 17.07.26on TipRanks 05:55 | +0.9%next day +3.4% · 5 days +11.5% | ↗ |
| Alexander Nowak★★★★★★★★★★#4079 · hits 41% · avg +3.2% | Lucid Capital | $10.00 | Buy | +144.5% | Initiated | 22.06.26on TipRanks Jun 25 21:13 | +2.2%next day +3.1% · 5 days +5.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering FocalTherics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $9.67 at a price of $4.47 (+116.3%); now: $7.00 at $4.09 (+71.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.24 (from $-0.33 to $-0.17). Last quarter: $-0.39.
Sales
Next quarter’s sales estimate — $11M (from $11M to $12M). Last quarter: $13M.
Best top-analyst consensus in the sector · Healthcare
About FocalTherics
- CEO: Ryan Rhodes
- Employees: 289
- Parc d’Activites la Poudrette-Lamartine, Vaulx-en-Velin, ARA, 69120, FR
- www.focalone.com
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Data from the stock’s TipRanks forecast page, read 306 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗